Sucampo Pharmaceuticals, Inc.
SCMP
SCMP was delisted on the 12th of February, 2018.
69 hedge funds and large institutions have $49.1M invested in Sucampo Pharmaceuticals, Inc. in 2013 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 32 increasing their positions, 25 reducing their positions, and 4 closing their positions.
28% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 25
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
1% more funds holding
Funds holding: 68 → 69 (+1)
10% less capital invested
Capital invested by funds: $54.8M → $49.1M (-$5.69M)
98% less call options, than puts
Call options by funds: $7K | Put options by funds: $363K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$4.22M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$749K |
| 3 |
CCM
Cadence Capital Management
Boston,
Massachusetts
|
+$516K |
| 4 |
SO
STRS Ohio
Columbus,
Ohio
|
+$327K |
| 5 |
LOM
Loeb Offshore Management
New York
|
+$222K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NCM
Nantahala Capital Management
New Canaan,
Connecticut
|
-$2.11M |
| 2 |
Wells Fargo
San Francisco,
California
|
-$1.85M |
| 3 |
NI
Numeric Investors
Boston,
Massachusetts
|
-$1.55M |
| 4 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$1.36M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
-$943K |
SCMP Hedge Fund Activity: Q3 2013 in Review
69 of the 3,085 institutional investors tracked by Wall St. Rank reported a position in Sucampo Pharmaceuticals, Inc. (SCMP) for Q3 2013, worth a combined $49.1M — down 10% from $54.8M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new SCMP positions and 4 closed out — a net gain of 1 holder — while 32 added to existing stakes and 25 trimmed.
The largest buyer was Consonance Capital Management, adding an estimated $4.22M. The largest seller was Nantahala Capital Management, exiting entirely with an estimated $2.11M sold.
- 69 institutional investors held Sucampo Pharmaceuticals, Inc. (SCMP) as of Q3 2013, up from 68 in Q2 2013.
- Funds reported $49.1M of Sucampo Pharmaceuticals, Inc. stock for Q3 2013, down 10% quarter-over-quarter.
- 5 funds opened new Sucampo Pharmaceuticals, Inc. positions in Q3 2013 and 4 closed out, a net change of +1 holder.
- The largest Sucampo Pharmaceuticals, Inc. buyer in Q3 2013 was Consonance Capital Management, an estimated $4.22M added.
- The largest Sucampo Pharmaceuticals, Inc. seller in Q3 2013 was Nantahala Capital Management, an estimated $2.11M sold.
Based on aggregated 13F filings for Q3 2013.